Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.
Roviello G, Petrioli R, Marano L, Polom K, Marrelli D, Perrella A, Roviello F. Roviello G, et al. Among authors: petrioli r. Gastric Cancer. 2016 Jan;19(1):31-41. doi: 10.1007/s10120-015-0537-5. Epub 2015 Sep 2. Gastric Cancer. 2016. PMID: 26329368 Review.
Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients.
Correale P, Cerretani D, Marsili S, Pozzessere D, Petrioli R, Messinese S, Sabatino M, Roviello F, Pinto E, Francini G, Giorgi G. Correale P, et al. Among authors: petrioli r. Eur J Cancer. 2003 Jul;39(11):1547-51. doi: 10.1016/s0959-8049(03)00361-7. Eur J Cancer. 2003. PMID: 12855261 Clinical Trial.
Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer.
Petrioli R, Sabatino M, Roviello F, Marrelli D, Nastri G, Marsili S, Correale P, Pozzessere D, Messinese S, De Martino A, Tani F, Marzocca G, Lorenzi M, Civitelli S, Tanzini G, Pinto E, Francini G. Petrioli R, et al. Hepatogastroenterology. 2005 Sep-Oct;52(65):1626-30. Hepatogastroenterology. 2005. PMID: 16201130
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
Petrioli R, Pascucci A, Francini E, Marsili S, Fiaschi AI, Civitelli S, Tanzini G, Battistelli S, Lorenzi M, Roviello F, Francini G; Multidisciplinary Oncology Group on Gastrointestinal Tumors. Petrioli R, et al. Anticancer Drugs. 2008 Jan;19(1):91-6. doi: 10.1097/CAD.0b013e3282f21363. Anticancer Drugs. 2008. PMID: 18043134
Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel.
Francini F, Pascucci A, Francini E, Bargagli G, Conca R, Licchetta A, Roviello G, Martellucci I, Chiriacò G, Miano ST, Marzocca G, Manganelli A, Ponchietti R, Savelli V, Petrioli R. Francini F, et al. Among authors: petrioli r. Prostate Cancer. 2011;2011:258689. doi: 10.1155/2011/258689. Epub 2011 Aug 21. Prostate Cancer. 2011. PMID: 22096653 Free PMC article.
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
Petrioli R, Licchetta A, Roviello G, Pascucci A, Francini E, Bargagli G, Conca R, Miano ST, Marzocca G, Francini G; Multidisciplinary Oncology Group On Gastrointestinal Tumors. Petrioli R, et al. Cancer Invest. 2012 Jan;30(1):65-71. doi: 10.3109/07357907.2011.629380. Cancer Invest. 2012. PMID: 22236191
146 results